A grayish or yellowish white elongated foaming tablets with a smooth and homogenous surface, produced in moisture-proof polyethylene film or metal foil blister packs containing 2, 4, 8, 10, 12, 20 tablets each placed in carton boxes or plastic cans.
In the liquid medium at 37-38 °C ENROFLON« foaming tablets produce ample and stable foam.
ENROFLON« intrauterine foaming tablet contains 0.36g of enrofloxacin.
Enrofloxacin possesses a wide spectrum of antibacterial properties and is active against gram-positive and gram-negative bacteria, including E.coli, haemophilus, klebsiella, pasteurella, pseudomonas, bordetella, campylobacter, erysipelothris, corynebacterium, staphylococcus, streptococcus, actinobacillus, clostridium, bacteroides, fusobacterium, as well as Mycoplasma spp. Bacteria resistance to ENROFLON« develops relatively slowly, as the mechanism of antimicrobial action of enrofloxacin is based on the inhibition of the activity of gyrase ferment affecting the DNA replication in the core of the bacterial cell.
Due to the foam-forming basis the agent is evenly distributed along the mucous membrane of the alvus. The resulting carbon dioxide enhances the resorption of enrofloxacin and causes its penetration in the deeper layers of the endometrium. Enrofloxacin is partially metabolized in liver with producing of ciprofloxacin, possessing of antibacterial activity. Fluoroquinolones are effused from the organism primarily in urine and bile.
ENROFLON« foaming tablets are used for the prevention and treatment of inflammations in the uterus after obstetrics, operative expulsion of afterbirth, abortions, complicated and pathological delivery, acute puerperal endometritis in cows.
For prevention purposes ENROFLON« foaming tablets are administered once in the dose of one tablet immediately after the expulsion of afterbirth, abortion or obstetrics is case of complicated or pathological delivery. For treatment purposes ENROFLON« foaming tablets should to be administrated in the dose of 1 ľ 2 tablets every 24 hours, 2 or 3 times until the clinical recovery of the animal.
No contradictions, adverse reactions or complications caused by the administration of ENROFLON« foaming tablets in line with the prescription have been registered. Enrofloxacin should not be used together with bacteriostatic antibiotics (tetracycline, macrolide and chloramphenicol), teophyllin, steroids and indirect anticoagulants.
Milk from cows treated with ENROFLON« foaming tablets should not be used for nutrition purposes during treatment and within 3 days after the last administration of the drug. Such milk can be used only for animal nutrition after boiling.
Livestock slaughter and butchering is allowed only 3 days after the last administration of ENROFLON« foaming tablets. Meat of animals slaughtered prior to the indicated period can be used for mink feeding or production of tankage.
ENROFLON« intrauterine foaming tablets should be stored with precaution (List B) at no more than 25 °C in a dry place away from direct light. Validity period in the prescribed conditions ľ 3 years from the date of production.